No approved hantavirus vaccine exists for human use in the United States or Europe as of mid-2026, driving the 94.5% market-implied odds against availability this year. Multiple DNA vaccine candidates targeting glycoproteins like Gn-Gc have advanced only to Phase 1 or 2 trials, with ongoing preclinical work on mRNA and subunit approaches following 2026 outbreaks linked to Andes virus transmission. Regulatory pathways require completed Phase 3 efficacy data and safety reviews that current pipelines cannot meet before year-end, consistent with historical timelines for similar rare-disease vaccines. Accelerated emergency authorization during a large-scale outbreak remains a low-probability disruptor, though model consensus and trial status indicate limited near-term feasibility.
Tóm tắt AI thử nghiệm tham chiếu dữ liệu Polymarket. Đây không phải tư vấn giao dịch và không ảnh hưởng đến cách thị trường này được giải quyết. · Cập nhậtHantavirus vaccine in 2026?
Hantavirus vaccine in 2026?
6% khả năng
$129,600 KL.
$129,600 KL.
Dec 31, 2026
6% khả năng
$129,600 KL.
$129,600 KL.
Dec 31, 2026
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.No approved hantavirus vaccine exists for human use in the United States or Europe as of mid-2026, driving the 94.5% market-implied odds against availability this year. Multiple DNA vaccine candidates targeting glycoproteins like Gn-Gc have advanced only to Phase 1 or 2 trials, with ongoing preclinical work on mRNA and subunit approaches following 2026 outbreaks linked to Andes virus transmission. Regulatory pathways require completed Phase 3 efficacy data and safety reviews that current pipelines cannot meet before year-end, consistent with historical timelines for similar rare-disease vaccines. Accelerated emergency authorization during a large-scale outbreak remains a low-probability disruptor, though model consensus and trial status indicate limited near-term feasibility.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
Thị trường mở: May 4, 2026, 10:39 AM ET
Khối lượng
$129,600Ngày kết thúc
Dec 31, 2026Thị trường mở
May 4, 2026, 10:39 AM ETResolver
0x65070BE91...This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.No approved hantavirus vaccine exists for human use in the United States or Europe as of mid-2026, driving the 94.5% market-implied odds against availability this year. Multiple DNA vaccine candidates targeting glycoproteins like Gn-Gc have advanced only to Phase 1 or 2 trials, with ongoing preclinical work on mRNA and subunit approaches following 2026 outbreaks linked to Andes virus transmission. Regulatory pathways require completed Phase 3 efficacy data and safety reviews that current pipelines cannot meet before year-end, consistent with historical timelines for similar rare-disease vaccines. Accelerated emergency authorization during a large-scale outbreak remains a low-probability disruptor, though model consensus and trial status indicate limited near-term feasibility.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
Khối lượng
$129,600Ngày kết thúc
Dec 31, 2026Thị trường mở
May 4, 2026, 10:39 AM ETResolver
0x65070BE91...No approved hantavirus vaccine exists for human use in the United States or Europe as of mid-2026, driving the 94.5% market-implied odds against availability this year. Multiple DNA vaccine candidates targeting glycoproteins like Gn-Gc have advanced only to Phase 1 or 2 trials, with ongoing preclinical work on mRNA and subunit approaches following 2026 outbreaks linked to Andes virus transmission. Regulatory pathways require completed Phase 3 efficacy data and safety reviews that current pipelines cannot meet before year-end, consistent with historical timelines for similar rare-disease vaccines. Accelerated emergency authorization during a large-scale outbreak remains a low-probability disruptor, though model consensus and trial status indicate limited near-term feasibility.
Tóm tắt AI thử nghiệm tham chiếu dữ liệu Polymarket. Đây không phải tư vấn giao dịch và không ảnh hưởng đến cách thị trường này được giải quyết. · Cập nhật
Cẩn thận với liên kết bên ngoài.
Cẩn thận với liên kết bên ngoài.
Câu hỏi thường gặp